The Challenge, Promise of Getting Oral COVID Drugs Into Practice

Effective oral therapeutics may be the "holy grail" for COVID treatments, but getting them from into practice can be a labyrinthine process, regardless of the need or desire for the drugs.

Related Keywords

Brazil , United States , United Kingdom , Massachusetts , Boston , University Of Southern California , California , San Francisco Bay , San Francisco , America , American , David Boulware , Jeff Klausner , Susanna Naggie , Janet Woodcock , Paul Sax , Brandon Shumway , Barbara Kilian , Norman Hearst , Carolyn Bramante , University Of California , Parsemus Foundation , Lancet Global Health , Medscape Coronavirus Resource Center , Rainwater Charitable Foundation , Pfizer , University Of Minnesota , Facebook , Central Valley Indian Health In Clovis , Division Of Infectious Diseases At Brigham , National Institutes Of Health , Drug Administration , Harvard Medical School , Infectious Diseases Society Of America , Duke University , Coronavirus Resource , Medscape Medical , San Francisco Bay Area , National Institutes , American Rescue Plan Act , Central Valley Indian Health , Infectious Diseases , Johns Hopkins Medicine , Infectious Diseases Society , Cliff Lane , Public Readiness , Emergency Preparedness , Coronavirus , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Covid 19 Treatment , Clinical Research , Clinical Trials , Linical Studies , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Obsessive Compulsive Disorder Ocd , Obsessive Compulsive Disorder , Cd , Treatment Gu ,